header logo image


Page 32«..1020..31323334..4050..»

Archive for the ‘Diabetes’ Category

Researchers found a cure for diabetes (in lab mice) – The Next Web

Thursday, February 27th, 2020

More than 34 million Americans have diabetes, approximately 10% of the population according to the American Diabetes Association. To date, the most common treatment has been to manage the disease with a carefully controlled diet and regular insulin shots, if needed. But a cure may be on the horizon.

A research team led by Jeffrey Millman at Washington University in St. Louis, Missouri found last year that infusing mice with stem cells could offer a better treatment option.

Building on that research, the same team may have found a cure: at least in lab mice.

Diabetics are characterized by their difficulty producing or managing insulin. This requires careful monitoring, a strict diet, exercise, and expensive insulin shots which many diabetics find themselves rationing due to the cost of drugs in the United States. Insulin is normally produced in the pancreas, but those with diabetes dont produce enough of it. To treat diabetes, many diabetics have to monitor their blood sugar levels, and inject insulin directly into the bloodstream as needed. Millmans treatment foregoes these shots and instead uses beta cells to secrete the insulin for you.

The treatment relies on induced pluripotent stem cells (iPS cells). These cells are essentially a blank slate and can be tricked into becoming almost any other type of cell in the body.

In a new study, the team improved on the technique it had developed last year to produce and introduce these cells into the bloodstream. When converting the stem cells into another type of cell, there are always mistakes and random cells enter into the mix along with the insulin-producing ones. These cells are harmless, but they dont pull their weight.

The more off-target cells you get, the less therapeutically relevant cells you have, Millman told New Atlas. You need about a billion beta cells to cure a person of diabetes. But if a quarter of the cells you make are actually liver cells or other pancreas cells, instead of needing a billion cells, youll need 1.25 billion. It makes curing the disease 25% more difficult.

The new method would rid the sample of those unwanted cells. Millmans team built a process that targeted the cytoskeleton, the structure that gives the cells their shape, and produced not only a higher percentage of effective beta cells, but better functioning ones.

When these new cells were infused into diabetic mice, their blood sugar levels stabilized, leaving them functionally cured of the disease for up to nine months.

Granted, its just an animal trial. The results shouldnt be interpreted as a cure for humans. But its a promising start.

The team plans to continue testing the cells in larger animals, and over longer periods, with their sights set on human clinical trials in the future.

Read next: Smithsonian Institute just released 2.8 million high-quality images for free

Read more:
Researchers found a cure for diabetes (in lab mice) - The Next Web

Read More...

Diabetic Patients Get Ready: An Oral Insulin Capsule That May Soon Be On The Market – Forbes

Thursday, February 27th, 2020

Nearly half a billion people worldwide suffer from diabetes.

Many will eventually have no other option but to use insulin. Until now, insulin was only available via injection or an inhaler. One company just took a huge step towards a much-anticipated alternative: an Insulin capsule.

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, just announced unprecedented topline data from the second and final cohort of its Phase 2b trial evaluating the efficacy and safety, at lower dose regimens, of its lead oral insulin capsule, ORMD-0801.

While many huge corporations have spent millions of dollars trying to create an oral insulin pill, none have succeeded so far. This new development, which signals the first commercial oral insulin capsule for the treatment of type 2 and type 1 diabetes, might be the game-changer that revolutionizes the treatment of diabetes.

Established in 2006, with offices in New York and Israel, Oramed has developed a Protein Oral Delivery technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

The options of diabetics.

Since insulin was first discovered, it has been impossible to deliver it orally, because of degradation and factors affecting absorbance; since insulin is a protein, the body breaks it down when ingested. The company uses enteric coating and special protection which allows the insulin to stay intact through the GI tract and reach the intestinal wall. Via special absorption enhancers, the insulin can pass through this wall and into the liver, where it starts working. Importantly, it mimics the natural path of insulin in the body, by heading to the liver first.

Although diabetes has spread rapidly, the average person knows very little about living with this chronic condition. In addition to pain, inconvenience, visible scars and dependence, many patients living with diabetes simply cannot afford to keep up with the rising costs of insulin. According to one Washington Post report, because of the skyrocketing prices of insulin, some desperate diabetics are rationing the drug and putting their lives at risk as a result.

Researchers also found that many diabetes patients were cutting back on insulin due to its high cost. Other studies estimate that at least 25 percent of patients with diabetes are not taking the insulin prescribed to them.

Oramed CEO Nadav Kidron is confident that the cost of the pill will be significantly lower (by tens of percent) than the cost of insulin injections.

Nadav Kidron, Oramed CEO.

In addition, treatment with the capsule at all doses demonstrated an excellent safety profile, with no serious drug-related adverse events and no increased frequency of hypoglycemic episodes or weight gain, compared to placebo. The statistically significant efficacy data, says Joel M. Neutel, MD, Principal Investigator of the Phase 2b trial, coupled with a clean safety profile characterized by no reported weight gain, no increase in serious drug-related adverse events, and no hypoglycemia, further support its clinical potential. It further validates the clinical potential of oral insulin to have a highly beneficial impact on the treatment of diabetes worldwide.

A1C levels areakey indicator of diabetes.In this latest trial, patients who were treated with 8 mg of the capsule once daily achievedan observed mean reduction of 1.29% from the baseline anda least square mean reduction of 0.95% from baseline(0.81% placeboadjusted). Patients who had A1C readings above 9% at baseline and received 8 mg of oral insulin once daily experienced a 1.26%placebo adjustedreduction in A1C by week 12.

We are looking forward to discussing with the FDA our planned Phase 3 trial, concludes Kidron. We are additionally very pleased with the progress of our Chinese partners, HTIT, who will also be initiating Phase 3 trials for our oral insulin and might even become the first to reach commercialization."

Read this article:
Diabetic Patients Get Ready: An Oral Insulin Capsule That May Soon Be On The Market - Forbes

Read More...

Diabetes symptoms: What is the difference between Type 1 and Type 2 diabetes symptoms? – Express

Thursday, February 27th, 2020

What is Type 1 diabetes?

Type 1 diabetes is not caused by an unhealthy diet or poor lifestyle choices, but rather it is an autoimmune condition.

This means your immune system attacks itself instead of protecting your body from disease.

Your body attacks the cells in your pancreas responsible for making insulin, meaning you are unable to produce any of this essential hormone.

While you can live without insulin, it is responsible for glucose (sugar) in our blood entering our cells and fuelling our bodies.

Youre still able to break down carbohydrates and turn it into glucose but no insulin means the glucose cant get into your cells, causing a buildup of glucose in your bloodstream.

If left for a long period of time, high glucose levels in your blood can cause complications with your heart, eyes, feet, and kidneys.

Only eight percent of adults who have diabetes have Type 1, so its much less common than Type 2.

READ MORE:Type 2 diabetes symptoms: Look out for this sign in your nails

The symptoms for both types of diabetes are the same, but it is the speed in which they happen that is different.

With Type 1 diabetes, the symptoms pop up more quickly, so it may be easier to spot and get a diagnosis.

Type 2 symptoms might be less noticeable, since they appear more slowly.

There are more ways to manage Type 2 than Type 1.

Since Type 2 is connected to your health and lifestyle, you are able to exercise and change your diet in order to improve blood sugar levels without medication.

You cannot cure diabetes.

Type 1 is incurable, but research is continuing in the hope to find one.

Type 2 cannot be cured either, but a lot of people are able to get to a stable and normal blood sugar levels without medication and keep it there.

Even if you hold this healthy level, you arent cured- diabetes is an ongoing disease.

See the rest here:
Diabetes symptoms: What is the difference between Type 1 and Type 2 diabetes symptoms? - Express

Read More...

Escherichia coli and the Progression of Diabetes Mellitus: A Review – Infectious Disease Advisor

Thursday, February 27th, 2020

Diabetes mellitus (DM) is one of the leading causes of death globally.1 DM is a metabolic disorder characterized by hyperglycemia resulting from a low level or complete deficiency of insulin hormone.1,2 Insulin, synthesized by the cells of the pancreatic islets of Langerhans, plays a key role in modulating blood glucose levels.1,2 Type 1 DM (T1DM) is triggered by autoimmune destruction of pancreatic cells, which leads to an absolute insulin deficiency,1,2 whereas type 2 DM (T2DM) typically is caused by insulin resistance along with insufficient insulin secretion.1,2

With a rapid rise in incidence during the last 50 years, T1DM is one of the most frequent autoimmune disorders in childhood and adolescence.3,4 T1DM is generally associated with a long prediabetic seroconversion period, during which autoantibodies to antigens of pancreatic cells or insulin are produced.3,4 There are a few known factors that trigger autoimmunity during infancy, such as spontaneous cell death within the -cell population, deposition of islet amyloid polypeptide aggregates, or viral infection that specifically targets pancreatic cells and leads to islet cell death, which contribute to the formation of -cell antigens, activation of dendritic cells, and antigen presentation.3,4 However, the exact etiopathogenesis remains poorly understood.

In general, patients with diabetes are more prone to microbial infections, which have been postulated to have a causal relationship with high blood glucose levels. However, it is little known about the role of therapeutic insulin administration on dissemination of infectious diseases in people with DM.2

Effect of Gut Microbiome

The increase in incidence of T1DM may not be solely a result of genetics and environmental factors, but also that of gut microbiota.3,4 Given the overarching influence of gut bacteria on human health, including its association with the functions of the bodys immune system and intestinal permeability, accumulating data suggest the gut microbiome may contribute to the pathogenesis of T1DM.3,4

The microbiota of the human intestinal tract is composed of bacteria, fungi, and eukaryotic and bacterial viruses (bacteriophages).3,4 Bacteria in the human gut live within surface-associated microbial communities, termed biofilms, which are characterized by the presence of self-produced extracellular matrix and a surface film that protects the microorganisms from the outer environment.3,4 Moreover, several studies have shown that the development of T1DM may be driven by some forms of bacteria.3,4

E coli

Among the aforementioned bacteria, the most common etiologic agent has been found to be Escherichia coli.3,4 Although E coli plays a protector role for the gut microbiome, E coli can affect all organs and systems and is a major cause of extraintestinal infections in patients with diabetes.3,4 E coli is the causative agent for 70% cases of patients with DM with an emphysematous urinary tract infection and in 40% of those with emphysematous cholecystitis.3,4 Moreover, high blood sugar levels have been linked to E colis rapid multiplication and ability to establish more severe form of the infection.3,4 Consequently, individuals with diabetes may be at higher risk for moderate or severe infection-related morbidity.

Association Between E coli and DM

A separate study conducted by Madacki-Todorovic and colleagues presented evidence for the direct effect of insulin on increased metabolic activity of E coli in an association with its biofilm-forming capability.5 Patients with DM are at high risk of developing microbial infections, which are believed to be triggered by the hyperglycemic physiologic status they have and can compromise components of the immune system.5 Pathogenic microorganisms can lead to disease as a result of suppression of the host immune mechanisms. Yet scant evidence has been reported on the role of therapeutic insulin administration on dissemination of infectious diseases in people with DM.

Aside from human insulins influence on the growth kinetic of E coli, little is known about other effects of insulin on E coli in the course of systemic infection, and there is a lack of data on how insulin may affect metabolic activity of this pathogen and its ability to become a biofilm former. Consequently, the researchers of this study investigated the effect of hormone insulin on the expression of enzymatic virulent factors of E coli as the most common pathogen associated with morbimortality in patients with diabetes.5 Three strains of E coli (E coli-C1, E coli-C2, and E coli-C3) with robust biofilm-forming ability, together with nonbiofilm-former E coli strain (E coli-Ref) as the control, were isolated from clinical samples of patients by using conventional microbiologic identification and isolation methods.5

A key defining characteristic of microorganisms such as E coli is their ability to grow and multiply in different environments if they have all necessary nutritive supplements. Therefore, all E coli strains were incubated in growth media at 37 C for different incubation times with the addition of human insulin in dosing concentration of 2.5 U/mL.5 The results demonstrated that insulin administration had a significant stimulatory effect on E coli proliferation of all tested E coli strains, serving as an autoinducer or stimulatory agent for E coli infection and pathogenicity compared with control strains that were not supplemented with insulin and showed a significantly lower proliferation rate at all incubation times.5

Moreover, microbial proteases also play a crucial role in cell viability and virulence status of the microbe, and protease genes are new potential therapeutic targets in treatment of infectious diseases.5 Aspartyl proteinase of E coli is a catalytic type of enzyme that is released from the cell at higher concentration during the infection process of the host. Compared with control strains that were not supplemented with insulin, the presence of insulin also stimulated expression of E coli virulent factor enzyme aspartyl proteinase, which in synergism with human insulin served as signal molecules for bacterial quorum sensing and biofilm formation.5 This study demonstrated that human hormone insulin, even in this low concentration, not only had significant stimulatory effect on proliferation of bacterial cells but also significantly affected metabolic activity of E coli and acted as an autoinducer for biofilm formation.5 Based on these findings, the researcher reasonably identified human insulin as potential risk factor for dissemination of E coli infections and for the increase of related pathogenicity because of its stimulatory effect on the expression of aspartyl proteinase genes.5

A multidrug-resistant bacterium with biofilm-forming capacity can commonly cause devastating complications in patients with DM, including diabetic foot ulcers and diabetic foot infections.5 Results of this study also underline the need for development of alternative catheter materials that will not allow biofilm formation and guidelines in choice of catheters for patients with diabetes.5

Association between E coli and T1DM

A study conducted by Tetz et al revealed that there may be a correlation between a high level of amyloid-producing E coli in the intestinal tract, followed by their depletion resulting from prophage induction and the initiation of autoimmunity, and T1DM progression.3 In humans, pathologic depositions of insoluble amyloid aggregates have been shown to be associated with the development of T1DM, where an increased islet amyloid polypeptide concentration may constitute a risk factor for -cell destruction.3

As the gut microbiota is known to play a role in T1DM, Tetz and colleagues at the Human Microbiology Institute in New York City analyzed data from a prospective longitudinal microbiome cohort study by Kostic et al of 16 children (aged 0-3 years) with human leukocyte antigens (HLA)-susceptibility to T1DM, using an algorithm focusing on amyloid-producing bacteria.3,4 High-throughput shotgun sequencing was performed on the Illumina HiSeq500 platform for microbiota sequencing and processing.3 This analysis revealed an overlooked association between autoimmunity and the dynamics of gut amyloid-producing E coli.3

The findings demonstrated a different, dynamic relationship in children with HLA-conferred susceptibility to T1DM.3 E coli tended to disappear over time in patients with T1DM and patients who were seroconverters, whereas it increased and did not change significantly over time in children without HLA-conferred susceptibility to T1DM.3 E coli depletion was found before the appearance of antibodies, suggesting a role of E coli in disease onset.3 Moreover, their in vitro study revealed a highly immunogenic complex (amyloid curli-DNA composites) released from E coli biofilms upon prophage induction, which triggered the production of type I interferons through the TLR2/9 stimulation of -cells and DCs, and autoimmune cascade through the TLR-2-MyD88-NF-kB pathway. 3

This suggests that a leaky gut allows E coli amyloid-DNA complexes to pass to the lamina propria and trigger autoimmunity and T1DM progression.3 The researchers concluded that that E coli biofilm-derived highly immunogenic amyloid curly-DNA complexes might be involved in the activation of a prodiabetic pathway in children who are at a risk of T1DM. 3

In conclusion, E coli is a notorious pathogen with a broad spectrum of associated illnesses, including the progression of diabetes. These findings suggest that insulin may potentially be a risk factor for increased E coli virulence. Determining the exact role of E coli in the progression of diabetes may lead to novel diagnostics and interventional approaches; however, further detailed studies are required.

References

1. Baena-Diez JM, Penafiel J, Subirana I, Ramos R, Elosua R, Marin-Ibanez A, et al. Risk of cause-specific death in individuals with diabetes: A competing risks analysis. Diabetes Care. 2016;39(11):1987-1995.

2. Suri RS, Mahon JL, Clark WF, Moist LM, Salvadori M, Garg AX. Relationship between Escherichia coli O157:H7 and diabetes mellitus. Kidney International. 2009;75(Suppl 112):S44-S46.

3. Tetz G, Brown SM, Hao Y, Tetz V. Type 1 Diabetes: An association between autoimmunity, the dynamics of gut amyloid producing E. coli and their phages. Scientific Reports. 2019,9:9685.

4. Kostic AD, Gevers D, Siljander H, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host & Microbe. 2015;17(2):260-273.

5. Madacki-Todorovic K, Eminovic I, Mehmedinovic NI, Ibirisimovic M. Insulin acts as stimulatory agent in diabetes-related Escherichia coli pathogenesis. Int J Diabetes Clin Res. 2018;5(4):098.

The rest is here:
Escherichia coli and the Progression of Diabetes Mellitus: A Review - Infectious Disease Advisor

Read More...

Putting Diabetes Tools ‘in the Pocket’ Improves A1c Control – Medscape

Thursday, February 27th, 2020

Patients with type 2 diabetes who were part of a healthcare plan and used a computer and/or app on a mobile device to access a portal (website) with tools for managing diabetes were more adherent with prescription refills and had improved A1c levels, in a 33-month study.

The improvements were greater in patients without prior portal usage who began accessing the portal via a mobile device (smartphone or tablet) app as well as computer, as opposed to a computer only.

And the improvements were greatest in patients with poorly controlled diabetes (A1c >8%) who began accessing the portal by both means.

"Patients with greater clinical need were able to benefit even more from mobile portal access, both in taking their medications more often and in actually improving blood sugar levels," lead author Ilana Graetz, PhD, an associate professor at the Rollins School of Health Policy and Management, Emory University, Atlanta, Georgia, observed in a statement from Kaiser Permanente.

The results show that "patients can use technology to better manage their own care, their medications, and their diabetes," added senior author Mary Reed, DrPH, a research scientist at the Kaiser Permanente Division of Research, Oakland, California.

According to Reed, "This is an example of how the healthcare system, by offering patients access to their own information and the ability to manage their healthcare online, can improve their health."

"Offering this in a mobile-friendly way can give even more patients the ability to engage with their healthcare," she noted. "It literally puts the access to these tools in the patient's own pocket wherever they go."

The study was published online February 19 in JAMA Network Open.

Graetz and colleagues performed a retrospective analysis of data from 111,463 adults with type 2 diabetes who were not receiving insulin but were taking oral diabetes medications and were covered by a healthcare plan with Kaiser Permanente Northern California from April 1, 2015 to December 31, 2017.

Patients could register online for free access to a portal that allowed them to get general health information and see their laboratory test results, as well as securely send and receive messages to and from their healthcare providers, make medical appointments, and request prescription refills.

Study outcomes were change in oral diabetes medication adherence and A1c levels at 33 months.

Patients were a mean age of 64 years and 54% were men.

At baseline, 28% had poor medication adherence (monthly days covered <80%) and 20% had poor glycemic control (A1c >8%).

After 33 months, the proportion of patients who never accessed the diabetes management portal dropped from 35% to 25%, and the proportion who accessed it from both a computer and an app increased from 34% to 62%.

Among patients with no prior portal access who began accessing the portal by computer only, medication adherence increased by 1.16% and A1c dropped by 0.06%.

However, among patients with no prior portal access who began to access it using both a computer and an app, diabetes management improvement was greater: medication adherence increased by 1.67% and A1c dropped by 0.13%.

And among patients with no prior portal usage who had an initial A1c >8.0% and began to access the website by both means, medication adherence increased by 5.09%, equivalent to an added 1.5 medication-adherent days per month, and A1c levels fell by 0.19%.

There was also "a more modest but still statistically significant increase" of about 0.5 added medication-adherent days per month in patients with lower initial A1c levels who began accessing the portal both ways.

"While medication adherence measured by medication dispensed cannot guarantee which medications were actually used by patients," the authors write, "our findings of concurrent improvements in [A1c] levels confirm physiological improvements in diabetes control."

"Convenient access to portal self-management tools through a mobile device could significantly improve diabetes management," they conclude.

The study was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases. The authors have reported no relevant financial relationships.

JAMA Netw Open. 2020;3:e1921429. Full text

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

Read more from the original source:
Putting Diabetes Tools 'in the Pocket' Improves A1c Control - Medscape

Read More...

Diabetes, CVD Tied to Worse Prognosis for COVID-19 Infection – Medscape

Thursday, February 27th, 2020

Indications so far are that people with diabetes and other chronic medical conditions, such as cardiovascular disease (CVD), will have a worse prognosis if they become infected with COVID-19, the novel coronavirus that has emerged from China.

There is also evidence that diabetes may increase risk for infection from COVID-19 two- to threefold, independently of other medical problems, such as CVD.

Although more detailed analysis is needed to show a clearly defined connection between conditions such as diabetes and worse prognosis with COVID-19, the statistics suggest that this virus hits hardest among the most vulnerable, ie, the elderly and people with multiple medical problems, especially those with diabetes of long duration that has not been well controlled.

"The message we want to emphasize is that emergencies unmask vulnerabilities in diabetes. The old and the sick are the most vulnerable," Juliana C. N. Chan, MD, told Medscape Medical News in an interview.

Chan is director of the Hong Kong Institute of Diabetes and Obesity at the Chinese University of Hong Kong.

Chan and other experts are therefore calling for diabetes patients, those with CVD, and patients with other chronic medical conditions to be extra vigilant in their efforts to avoid contact with the virus, although they also note that individual responses vary greatly.

In past infectious disease outbreaks, including severe acute respiratory syndrome (SARS) and H1N1 flu, people with diabetes were at increased risk for severe illness and death.

"I don't think it's an overstatement to say that people with diabetes...are at higher risk of developing COVID-19, because the data are suggestive," noted Chan, although she cautioned that longer-term research will give a much clearer picture.

Chan was a senior coauthor on a study published last month in Diabetologia, as reported by Medscape Medical News, that found that mortality rates among people with diabetes in Hong Kong have plummeted in recent years except for young people, who may be more likely to have poorly controlled diabetes.

And importantly within the context of the COVID-19 outbreak although in that study deaths from most conditions such as CVD and cancer decreased among people with diabetes, deaths from pneumonia among people with diabetes remained about the same.

In serious cases of infection, the COVID-19 virus invades the cells that line the respiratory tract and lungs and enters the mucus, causing pneumonia. Severe lung damage from pneumonia can result in acute respiratory distress syndrome (ARDS), which in turn can cause septic shock.

ARDS and septic shock are the main causes of death from COVID-19.

So far, Hong Kong has had only 70 confirmed cases of COVID-19, although the first Hong Kong resident to die from the virus was a 39-year-old man with diabetes. That death was soon followed by a second death a 70-year-old man with diabetes and other medical problems, including high blood pressure and kidney disease.

"Our message is to ask people with diabetes to do things early in order to protect themselves and reduce their risk of having problems if anything happens," Chan emphasized to Medscape.

Although the mechanism of this increased susceptibility remains unclear, research suggests that high blood glucose levels may lead to reduced functioning of the immune system.

As of February 25, COVID-19 had infected about 80,000 people and had caused almost 2500 deaths worldwide.

Although the vast majority of these infections and deaths have been in China, there are now pockets of infection in Iran, Italy, Japan, and South Korea, as well as handfuls of cases in many other countries.

The World Health Organization (WHO) yesterday stopped short of calling the outbreak a pandemic but stressed that the status could change at any time.

Although COVID-19 appears to be highly transmissible, only a small percentage of people seem to develop severe illness, and an even smaller number die from the infection.

A recent study of 44,672 confirmed COVID-19 cases that had been reported through February 11 and that were analyzed by the Chinese Centers for Disease Control and Prevention (CCDC) shows that 80.9% of people in China who have been diagnosed with COVID-19 have had mild illness.

So far, the overall case fatality rate (CFR) in China is 2.3% less than previous coronavirus outbreaks caused by SARS (CFR: 9.6%) and Middle East respiratory syndrome (MERS) (CFR: 34.4%).

That said, because COVID-19 has infected far more people than SARS or MERS, the newest coronavirus on the block has already claimed many more lives.

This in turn raises the question: who is most at risk for severe illness and death from COVID-19?

Case fatality rates vary by factors such as age, sex, underlying medical conditions, and geography. Outside Hubei province in China, the epicenter of the outbreak, the CFR may be as low as 0.4%, compared to 2.9% within the province.

So far, for all age groups, the highest CFR is among people aged 80 years or older, at 14.8%. CFRs have been higher in people with other medical conditions than in healthy people.

CVD and diabetes top that list, at case fatality rates of 10.5% and 7.3%, respectively, compared to 0.9% for people without any prior disease, according to the aforementioned latest CCDC report.

Before publication of this report, two relatively small case series of patients who had been hospitalized for COVID-19 in Wuhan also suggested that older men with underlying medical problems, especially CVD and diabetes, are more likely to develop severe illness from the virus.

However, experts caution that for COVID-19 and similar infections, several factors may skew the data, making interpretation tricky.

"Cases that are identified tend to be in patients that have more severe illness, compared to younger, healthier individuals who just stay home and don't seek medical care," said Preeti N. Malani, MD, an infectious disease specialist and chief health officer at the University of Michigan Medical School, Ann Arbor.

"This is also the case with individuals who are sick enough to be hospitalized. There are more people with more chronic conditions, including diabetes [among hospitalized individuals]," Malani told Medscape via email.

"In general, diabetes can be a marker of other chronic health conditions like heart disease as well as obesity, which might contribute to the increased risk of infection," Malani added.

"Diabetes is also much more common with age and will continue to be a marker of poor outcomes for [all of] these reasons," she said.

All of this makes it tricky to tease out diabetes' individual contribution to infection risk.

"The proportion in which each medical condition contributes to...risk of infection is hard to dissect out," explained Andrea Luk, MBChB, FHKCP, FHKAM.

Luk is an associate professor at the Chinese University of Hong Kong and is the other senior coauthor of the study in Diabetologia.

"Certainly a person with both diabetes and cardiovascular disease would have more risk than someone with diabetes and good glucose control and without any other comorbidities," she continued.

But because every person with diabetes is different, it is important to consider the whole package, she stressed.

Whether someone with diabetes succumbs to infection has a lot to do with glycemic control, diabetes duration, and diabetes-related comorbid conditions, such as heart disease, kidney disease, and stroke, as well as their age, weight, and whether they smoke.

Chan further clarified: "We have to judge this case by case. You cannot apply it across the board to all people with diabetes. A person with well-controlled diabetes is very different from someone with poorly controlled diabetes. They have a different set of risk factors and complications."

While awaiting more detailed analysis, Chan, Luk, and Malani all suggest common-sense measures for patients with diabetes, CVD, and other chronic conditions: staying up to date with vaccinations, avoiding large crowds, frequent hand washing, avoiding touching eyes or mouth (the so-called T-zone), and wearing face masks in areas where COVID-19 is prevalent.

People with symptoms should also wear a face mask to avoid spreading infection to others.

Malani added, "Although there is a lot of focus and concern about COVID-19, this has [also] been a terrible year for seasonable flu. I recommend flu shots, especially for...patients with diabetes."

She also suggested being thoughtful about travel.

"This may not be a good time for nonessential travel to Asia, as the situation there is evolving. COVID-19 risk is still low, depending on where you go, but the risk of disrupted travel is real," she noted.

Even without an emergency such as COVID-19, Chan and Luk say they cannot stress highly enough the importance of optimal glucose control for people with diabetes.

"People with diabetes or other chronic conditions should be extra vigilant about protecting themselves from infection," Luk reiterated.

They should also have a lower threshold for seeking care if they feel they are developing symptoms of infection, she noted.

"It's hard to tell at the beginning whether it's influenza or COVID-19 because they present similarly," she said.

Chan, Luk, and Malani have disclosed no relevant financial relationships.

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

Read more from the original source:
Diabetes, CVD Tied to Worse Prognosis for COVID-19 Infection - Medscape

Read More...

FDA Clears InPen Diabetes Management System for Fixed Dosing and Meal Estimation – PRNewswire

Thursday, February 27th, 2020

Companion Medical today confirmed that it has received clearance from the FDA for its InPen bolus calculator for fixed dosing and meal estimation. The new bolus calculator takes into consideration each user's current glucose level and active insulin - the calculation of the amount of insulin still lowering glucose from previous bolus doses, removing the guesswork from insulin dosing. This is the first time a clearance like this has been issued for those with Type 1 or Type 2 insulin-dependent diabetes who administer a fixed amount of insulin for meals or deliver a dose based on the approximate size of their planned meal, as opposed to individual carb estimations. These new capabilities allow InPen to help the majority of patients using multiple daily injections, regardless of their personal insulin regimen.

"Our goal since launching in 2017 has been to make insulin therapy simpler for all people with diabetes - not just the most engaged or advanced. We do this by letting the InPen system do most of the heavy lifting and ease the burden," said Sean Saint, CEO and founder of Companion Medical. "Similar to the first InPen dose calculator, which has been a game-changer for those of us who count carbs, this new FDA clearance for users on fixed-dose or meal estimation therapy finally offers a simple, yet advanced solution to those people living with insulin-dependent diabetes who are not expert carb counters."

"The biggest predictor of better control amongst people living with diabetes is the number of insulin doses per day. Patients without a dose calculator with active insulin tracking have been taught for years to dose at least four hours apart because of the dangers of insulin stacking - this allows for only a maximum of three or four doses per day," said Mike Mensinger, CTO and co-founder at Companion Medical. "With the new calculator modes, InPen provides an experience consistent with these patients' current therapies, while adjusting recommendations automatically based on their current glucose level and factoring in active insulin to safely allow correction of high blood glucose between meals."

"This feature allows insulin pen users to be met where they are in their therapy," said Janice MacLeod who leads Companion Medical's clinical advocacy efforts. "The clinicians I have spoken to are excited about this feature for their patients, in particular those with Type 2 diabetes who inject insulin. Not all patients are able or wish to, count carbs for every meal, and the option of correction doses informed by InPen's active insulin tracking is incredibly useful in helping users avoid stacking their insulin and minimizing their risk of low glucose."

The InPen system, which includes a smart pen and Bluetooth connected app, helps calculate insulin doses, issue dose reminders, track active insulin and send reports to caregivers. InPen is available in the U.S. by prescription only. The app is available for download on the Apple App Store and Google Play. For more information, visit http://www.companionmedical.com.

About Companion Medical Companion Medical develops easy-to-use, affordable diabetes technology focused on advanced insulin delivery and real-time actionable insights. The company's flagship product, InPen, is the first FDA-cleared smart insulin pen and mobile app-based diabetes management system providing people with diabetes and healthcare providers with essential data to optimize insulin regimens.

SOURCE Companion Medical, Inc.

Home

Go here to read the rest:
FDA Clears InPen Diabetes Management System for Fixed Dosing and Meal Estimation - PRNewswire

Read More...

This is to seal it as Tandem Diabetes Care, Inc. (TNDM) shares are up 61.59% from its 52-week low – The InvestChronicle

Thursday, February 27th, 2020

At the end of the latest market close, Tandem Diabetes Care, Inc. (TNDM) was valued at $77.94. In that particular session, Stock kicked-off at the price of $77.72 while reaching the peak value of $79.97 and lowest value recorded on the day was $75.46. The stock current value is $76.53.

Tandem Diabetes Care, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $91.65 on 02/20/20, with the lowest value was $47.36 for the same time period, recorded on 04/18/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Tandem Diabetes Care, Inc. shares are logging -16.50% during the 52-week period from high price, and 61.59% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $47.36 and $91.65.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.5 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Tandem Diabetes Care, Inc. (TNDM) recorded performance in the market was 28.38%, having the revenues showcasing 11.84% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.62B, as it employees total of 653 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 66.39, with a change in the price was noted +21.78. In a similar fashion, Tandem Diabetes Care, Inc. posted a movement of +39.78% for the period of last 100 days, recording 1,517,027 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for TNDM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Tandem Diabetes Care, Inc. in the period of last 50 days is set at 55.32%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 28.98%. In the last 20 days, the companys Stochastic %K was 50.33% and its Stochastic %D was recorded 68.74%.

Bearing in mind the latest performance of Tandem Diabetes Care, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 28.38%. Additionally, trading for the stock in the period of the last six months notably improved by 9.56%, alongside a boost of 54.89% for the period of the last 12 months. The shares increased approximately by 10.45% in the 7-day charts and went down by -15.00% in the period of the last 30 days. Common stock shares were driven by 11.84% during last recorded quarter.

Original post:
This is to seal it as Tandem Diabetes Care, Inc. (TNDM) shares are up 61.59% from its 52-week low - The InvestChronicle

Read More...

Unique diabetes and infection network launched – United News of India

Thursday, February 27th, 2020

More News27 Feb 2020 | 11:51 PM

New Delhi, Feb 27 (UNI) Aam Aadmi Party on Thursday night suspended its councillor Tahir Hussain after he was booked by the Delhi Police over the charges of murder of Intelligence Bureau staffer Ankit Sharma.

New Delhi, Feb 27 (UNI) Aam Aadmi Party (AAP) councillor Tahir Hussain was booked by the Delhi Police on Thursday over the charges of murder of Intelligence Bureau staffer Ankit Sharma.

New Delhi, Feb 27 (UNI) As many as 112 evacuees including 36 foreigners, who arrived from the Coronavirus epicenter Wuhan in China, were taken to makeshift quarantine facility of Indo Tibetan Border Polices(ITBP) at Chhawla here on Thursday.

New Delhi, Feb 27 (UNI) The Congress on Thursday demanded Home Minister Amit Shah's resignation over the 'failure' of National Investigating Agency (NIA) to file a chargesheet against the accused of Pulwama attack, a claim which the NIA has refuted.

New Delhi, Feb 17 (UNI) Amid the media reports of Pulwama Attack case accused getting bail by the Special Court, the National Investigation Agency (NIA) on Thursday clarified that Yusuf Chopan alias Mehraj-ud-din Chopan was never arrested in the Pulwama attack case that killed 40 jawan of Central Reserve Police Force on February 14, 2019.

See the original post here:
Unique diabetes and infection network launched - United News of India

Read More...

40% of People with Type 2 Diabetes Initially Avoid Insulin Therapy – Healthline

Monday, February 24th, 2020

More than 30 million Americans are estimated to have type 2 diabetes, a progressive blood sugar disease in which the body doesnt make enough insulin or use insulin well enough to break down the amount of sugar in the blood.

Medications, lifestyle changes, and in more serious cases, insulin therapy can manage the condition.

But a significant portion of people with diabetes often initially decline insulin therapy, according to new research from Brigham and Womens Hospital.

The study, which published in Diabetic Medicine on Thursday, found that more than 40 percent of people with type 2 diabetes turn down their doctors recommendation of insulin therapy.

But those who delay insulin therapy face challenges.

Compared with those who began insulin therapy, people who refused had worse glycemic control, and it took them longer to reach healthier blood sugar levels.

Researchers evaluated 15 years of health data from 5,307 adults with type 2 diabetes whose doctors had recommended they try insulin therapy.

Of the group, 2,267 people or 42.7 percent declined insulin therapy, and, in the years that followed, had worse glycemic control than those who started it.

Older adults were more likely to decline insulin therapy, as were those already taking other diabetes medications that werent insulin.

According to the researchers, the findings imply that delaying insulin therapy could have severe health consequences and shorten a persons life span.

It also highlights the need to improve how various treatment options are discussed with people with diabetes, all while considering each individuals preferences and risk factors.

These findings highlight the need to improve our understanding of the relationship of this common but poorly explored clinical phenomenon to blood glucose control and ultimately diabetes complications, the researchers state in the study.

In people without diabetes, the pancreas secretes the hormone insulin, which regulates blood sugar levels. Insulin is what prevents excessively high or extremely low levels of sugar in the blood.

With type 2 diabetes, the insulin function is impaired, and the body is unable to properly metabolize sugar, or glucose, in the blood.

Patients with diabetes either dont make enough insulin or they make insulin but [develop] resistance to that insulin, meaning that insulin doesnt work as well as it should, said Dr. Minisha Sood, an endocrinologist at Lenox Hill Hospital in New York City.

Oftentimes, people with diabetes need to take insulin therapy to help the body clear excess sugar from the blood before complications arise.

It is essential to get blood sugars under good control because high sugars can lead to fatigue, excessive urination and thirst, and unintentional weight loss as well as hospitalization or death in the most severe cases, said Dr. Patricia R. Peter, an endocrinologist with the Diabetes Center at Yale Medicine.

High blood sugar levels can also damage nerves, kidneys, vision, and blood vessels which can trigger organ failure, a heart attack, or stroke.

In short, insulin therapy can be lifesaving for people with diabetes.

Its unclear why so many people with diabetes decline insulin therapy.

According to Peter, many may fear the stigma linked to insulin therapy.

Some people equate insulin treatment with some of the most dreaded complications of diabetes, erroneously thinking that insulin will lead to a worsening of diabetes rather than realizing that it is often a necessary treatment when the disease itself is uncontrolled, Peter said.

Others believe insulin is a nuclear option, Peters adds only necessary for those whose condition is very advanced and potentially irreversible.

They may opt for an alternative treatment first.

Alternative therapies are not at all as effective as insulin therapy in lowering glucose, Sood said, adding that these treatments, like cinnamon supplements, inositol, and berberine, arent a substitute for insulin.

Theres also the side effects people hear about: weight gain, the self-injections, low blood sugar (hypoglycemia).

It may seem simpler to make some lifestyle changes first, and see whether that helps.

In my experience, some people with diabetes, when they are first diagnosed, are eager to make lifestyle changes to address the issue head-on in that manner. These patients may decline treatment at first, Sood said.

And then theres the high cost.

Its estimated that the average cost of insulin tripled between 2002 and 2013. The rising prices have caused some Americans to ration their insulin, or frantically sell their goods for cash to afford the therapy.

Whatever the reasons may be, its clear something needs to change to ensure people are getting the treatment they need to survive.

Theres a significant need to improve how treatment options are discussed with people who have type 2 diabetes and ensure theyre making fully informed choices.

The best approach, the researchers say, is to weigh the pros and cons of all the different treatment options and customize a plan thatll fit with their preferences along with their personal risks and benefits.

In many cases, though, insulin therapy can be the difference between life and death.

New research has found that more than 40 percent of people with type 2 diabetes turn down their doctors recommendation of insulin therapy.

And those who delay insulin therapy are worse off. Compared with those who began insulin therapy, people who refused had worse blood sugar control, and it took them longer to reach healthier blood sugar levels.

The findings show we need to improve how diabetes treatment options are discussed and ensure people with type 2 diabetes are making fully informed choices.

Excerpt from:
40% of People with Type 2 Diabetes Initially Avoid Insulin Therapy - Healthline

Read More...

Two million in UK at risk of type 2 diabetes as obesity crisis grows – The Guardian

Monday, February 24th, 2020

A record number of people are at risk of developing type 2 diabetes, increasing their chances of suffering a heart attack or stroke, the NHS has said.

A growing obesity crisis has led to nearly 2 million people in England being exposed to the condition that causes the level of sugar in the blood to become too high.

As part of efforts to tackle the problem, a radical new liquid diet will be available on the NHS to put type 2 diabetes into remission. Five thousand patients will be restricted to 800 calories per day for three months in a pilot to be rolled out from April. This will be followed by a further nine months of support to help them maintain weight loss.

According to new NHS figures, there are 1,969,610 patients registered with a GP who have non-diabetic hyperglycaemia, a condition that puts people at risk of type 2 diabetes.

The health service said the problem could become greater still because of the rise in obesity levels. Projections indicate the growing number of diabetes sufferers could lead to 39,000 extra people suffering a heart attack in 2035 and more than 50,000 experiencing a stroke.

The NHS said one in six hospital beds were occupied by someone with diabetes.

The most common form of diabetes, type 2, is caused by problems with how the insulin hormone breaks down glucose in the body. The lifelong condition can increase the risk of serious problems with the eyes, heart and nerves, and is often linked to being overweight or inactive.

According to the NHS, there were more than a million obesity diagnoses in hospital admissions last year, up from 884,000 the year before.

The NHSs world-first diabetes prevention programme is doubling its capacity to prevent people from developing the condition. The programme identifies people at high risk of diabetes and supports them to live healthier lives and stop or delay the onset of illness through courses that last between nine and 12 months. It has received around half a million referrals.

NHS chief executive Simon Stevens said bulging waistlines were leading to the rise in people living with type 2.

He said: Unless many more of us make a change, obesity-related illnesses will end up costing hundreds of thousands more lives and billions of pounds in higher treatment costs.

Prof Jonathan Valabhji, NHS national clinical director for obesity and diabetes, said the stark figures showed the problem was not limited to middle-aged or elderly people, with about 115,000 younger people suffering type 2 diabetes or at risk of developing the condition.

Chris Askew, chief executive at Diabetes UK, said: More than half of all cases of type 2 diabetes and the devastating complications it can lead to could be prevented or delayed by supporting people to reduce their risk by losing weight where appropriate, eating healthy food and being more active.

The rest is here:
Two million in UK at risk of type 2 diabetes as obesity crisis grows - The Guardian

Read More...

Beta-cell dysfunction typifies type 2 diabetes without obesity – Healio

Monday, February 24th, 2020

The response to a glucose-potentiated arginine test varied between those with and without obesity among a cohort of adults with type 2 diabetes, particularly in insulin sensitivity and proinsulin secretory ratio, which suggests that beta-cell function is compromised in patients without obesity, according to findings published in Diabetes/Metabolism Research and Reviews.

These data demonstrate that in nonobese type 2 diabetes, early in the disease course insulin secretion defects predominate with impaired beta-cell sensitivity to glucose and less efficient processing of proinsulin, together contributing to compromised beta-cell function, Michael R. Rickels, MD, MS, professor of medicine in the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues wrote. We did not find a significant reduction in insulin sensitivity in the nonobese type 2 diabetes subjects, supporting a primary beta-cell defect as the etiology of their impaired glucose regulation.

Rickels and colleagues employed a glucose-potentiated arginine test on 28 adults with type 2 diabetes and obesity (mean age, 54.7 years; 14 women), 12 adults with type 2 diabetes and no obesity (mean age, 58.8 years; one woman) and 12 adults with neither condition (mean age, 32.2 years; two women). The test allowed the researchers to assess acute insulin response to arginine, glucose potentiation of arginine-induced insulin release, beta-cell secretory capacity, beta-cell sensitivity to glucose, insulin sensitivity, the insulin secretion disposition index and the proinsulin secretory ratio. The researchers assessed the disposition index and proinsulin secretory ratio three times during the test.

The response to a glucose-potentiated arginine test varied between those with and without obesity among a cohort of adults with type 2 diabetes, particularly in insulin sensitivity and proinsulin secretory ratio, which suggests that beta-cell function is compromised in patients without obesity

Source: Adobe Stock

The researchers found that participants with type 2 diabetes and no obesity had greater proinsulin secretory ratios at the first (5 vs. 2.8), second (4.9 vs. 2.1) and third (2.6 vs. 1.7) assessment as well as greater insulin sensitivity (0.44 vs. 0.21 [mg/kg1/min1]/[U/mL]) compared with participants with type 2 diabetes and obesity (P < .05 for all). In addition, participants with type 2 diabetes and no obesity had greater levels of beta-cell sensitivity to glucose (208 vs. 160 mg/dL) compared with those without diabetes or obesity (P < .05). Participants with type 2 diabetes and no obesity also had a reduced mark on the disposition index on the second (28.6 vs. 54.5 mg/kg1/min1) and third (45.6 vs. 79.2 mg/kg1/min1) assessment compared with those without diabetes or obesity (P < .05 for both).

The present evidence supports the characteristic association of obese type 2 diabetes with insulin resistance, and that decreased beta-cell sensitivity to glucose and impaired proinsulin processing represent the predominant early pathophysiologic defects in nonobese type 2 diabetes, the researchers wrote. These findings help to differentiate a phenotype for the early presentation of type 2 diabetes wherein future therapeutic interventions may target beta-cell dysfunction as the primary defect in nonobese individuals and insulin resistance as the dominate problem in obese individuals. by Phil Neuffer

Disclosures: The authors report no relevant financial disclosures.

More:
Beta-cell dysfunction typifies type 2 diabetes without obesity - Healio

Read More...

Insulet Partners With Abbott and DexCom On Diabetes – Yahoo Finance

Monday, February 24th, 2020

Insulet Corp. (NASDAQ:PODD) hit its 52-week high on Feb. 19 after announcing formation of two partnerships that further strengthens its leading role in the market for continuous glucose monitoring.

Trading at just over $211 and with a market cap of more than $13 billion, the Acton, Massachusetts-based company may now be too pricey for both investors and potential acquirers. The company is on the list of the 25 most attractive public acquisition targets in medtech, according to an article in Medical Device and Diagnostic Industry that was updated in mid-2019.

Individual investors have to factor in the latest analyst projections for Insulet. According to CNN Business, the company is rated a hold by 18 analysts. Meanwhile, the 14 analysts offering a price target set the median at $185, with the high at $213 and the low at $125. The company reports fourth-quarter and full-year 2019 earnings on Feb. 25, so that's certainly something to keep an eye on. In the third quarter, Insulet revenue and earnings surpassed expectations.

Insulet's latest alliances are with Abbott Laboratories (NYSE:ABT) and DexCom Inc. (NASDAQ:DXCM). The focus of both deals is Insulet's Omnipod Horizon Automated Delivery System, which is being tested in the U.S. Omnipod will be united with Abbott's highly anticipated Freestyle Libre 2, which is awaiting Food and Drug Administration approval.

This agreement with Dexcom builds on the two companies' integration efforts and makes official plans to launch Omnipod.

DexCom's share performance during the past 52 weeks has been even better than Insulet's, with the price climbing more than 185%. The San Diego-based company sells at a lofty price-earnings ratio of more than 265. It's rated a buy, with 16 analysts assigning it a median target of $300, ranging between a high of $316 and a low of $270. Dexcom closed at $291 on Feb. 21.

Story continues

At least part of the enthusiasm for Insulet and DexCom has to be the size and growth rate for the market for CGM. It is expected to reach nearly $5 billion by 2024, advancing at a compound annual growth rate of nearly 23% from 2018 to 2024, according to a report from Allied Market Research. The monitoring systems enable patients to better manage diabetes by giving them real-time values of their glucose levels and alerts them if they approach hypoglycemia. One big issue facing the manufacturers is lack of reimbursement for the devices.

The International Diabetes Federation reports that about 463 million adults worldwide are living with diabetes; by 2045, this number will rise to 700 million. About 20% of people ages 65 and over have diabetes. The disease causes more than 4 million deaths a year.

Disclosure: The author holds no positions in any of the stocks mentioned in this article.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.

Read more:
Insulet Partners With Abbott and DexCom On Diabetes - Yahoo Finance

Read More...

Diabetic Neuropathy Market to Rise on the Back of Increasing Patient Pool, TMR – BioSpace

Monday, February 24th, 2020

Diabetes is common metabolic disorder that is found in 30 million people alone in the US. This means that nearly 9.4% of the US population are suffering from the diseases. Neuropathy is a common symptom in the diabetic patients.

A report by Transparency Market Research, forecasts the global diabetic neuropathy market to become worth US$5.718 bn by 2024 from US$ 3.6 bn in 2016 by rising at a steady CAGR of 5.4% between 2017 and 2025.

Diabetic neuropathies are a nerve disorders that can damage the nerves system within the body. Significant rise in the prevent in diabetic neuropathies due to the sedentary lifestyle and urbanization is a prominent factor expected to drive the global diabetic neuropathy market. Similarly, we have mentioned several other factors which are expected to boost he diabetic neuropathy market in the coming few years, have a look-

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2199

Asia Pacific to Witness Rapid Growth due to Rise in Aging Population

Europe and North America are likely to come up as a prominent regions in the global diabetic neuropathy market. Growth of the market in the North America region is mainly due to presence of large pool of patients affected with diabetes.

Request for Discount on this Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2199

On the other hand, Asia Pacific is likely to come up another highly promising region in the global diabetic neuropathy market. This growth of the region is ascribed to the better understanding of diabetic complications and considerable clinical developments. In the recent years, Asia Pacific has witnessed a rise in the number of patients suffering from diabetic neuropathy. Rise in incidences of diabetic neuropathy is mainly due to bad posture induced by change in lifestyle, genetic predisposition, and aging. These factors are driving the diabetic neuropathy market in Asia Pacific.

Johnson & Johnson Services, Inc., Glenmark Pharmaceuticals Ltd, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Arbor Pharmaceuticals, LLC, and Lupin Limited are some of the prominent players profiled in the report on the global diabetic neuropathy market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Read more:
Diabetic Neuropathy Market to Rise on the Back of Increasing Patient Pool, TMR - BioSpace

Read More...

Trulicity (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established…

Monday, February 24th, 2020

INDIANAPOLIS, Feb. 21, 2020 /PRNewswire/ --The U.S. Food and Drug Administration (FDA) has approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors. This decision makes Eli Lilly and Company's (NYSE: LLY) Trulicity the first and only type 2 diabetes medicine approved to reduce the risk of MACE for both primary and secondary prevention populations.*

The new indication reflects the differentiated patient population of REWIND, the Trulicity cardiovascular outcomes trial. While all participants had CV risk factors, the study consisted primarily of people without established CV disease. REWIND showed a significant risk reduction in MACE, a composite endpoint of nonfatal myocardial infarction (heart attack), nonfatal stroke or CV death. Results demonstrated consistent MACE risk reduction with Trulicity across major demographic and disease subgroups. Trulicity's safety profile was consistent with the GLP-1 receptor agonist (RA) class. The most common adverse events leading to the discontinuation of Trulicity were gastrointestinal events.

"The trial was designed to study a broad population of people living with type 2 diabetes, reflective of those in the general population. We therefore assessed the effect of Trulicity in people with established cardiovascular disease as well as those with multiple cardiovascular risk factors," said Hertzel Gerstein, M.D., MSc, FRCPC, professor of medicine and deputy director of the Population Health Institute at McMaster University and Hamilton Health Sciences, and the REWIND study chair. "Globally, over 415 million people have type 2 diabetes, which is itself a cardiovascular risk factor. However, only about one third have established cardiovascular disease, which is why this new indication, and the supporting evidence, is important for the millions of people in the U.S. living with diabetes."

"For the first time, health care providers can prescribe a diabetes medicine proven to significantly reduce the risk of experiencing a cardiovascular event for people with type 2 diabetes with and without established cardiovascular disease," said Sherry Martin M.D., vice president, medical affairs, Lilly. "Trulicity can help people achieve their A1C goals and protect them from experiencing a cardiovascular event with a once-weekly, easy-to-use treatment option."

Trulicity has been available in the U.S. since 2014 and is the number one prescribed GLP-1 RA. In addition to its proven glycemic efficacy and easy-to-use device**, Trulicity can now be prescribed to help people with type 2 diabetes reduce their risk of CV events.

About the REWIND StudyREWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) was a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the effect of Trulicity 1.5 mg, a weekly glucagon-like peptide 1 receptor agonist (GLP-1 RA), compared to placebo, both added to standard of care (according to local standard of care guidelines), on cardiovascular (CV) events in adults with type 2 diabetes. The primary CV outcome was the first occurrence of MACE (the composite of CV death or nonfatal myocardial infarction or nonfatal stroke). Secondary outcomes include each component of the primary composite CV outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. The 9,901 participants from 24 countries had a mean duration of diabetes of 10.5 years and a median baseline A1C of 7.2 percent. While all participants had CV risk factors, only 31.5 percent of the study participants had established CV disease. Prior (or established) cardiovascular disease in REWIND was defined as prior myocardial infarction, prior ischemic stroke, prior unstable angina, prior revascularization (coronary, carotid, or peripheral), prior hospitalization for ischemia-related events (unstable angina or myocardial ischemia on imaging, or need for percutaneous coronary intervention), or prior documented myocardial ischemia.

The REWIND trial's international scope, high proportion of women, high proportion of people without established cardiovascular disease and inclusion of participants with a lower mean baseline A1C suggest that the findings will be directly relevant to the typical type 2 diabetes patient seen in general practice.

PURPOSE AND SAFETY SUMMARY WITH WARNINGS

Important Facts About Trulicity (Tr-li-si-tee). It is also known as dulaglutide.

TRULICITY is an injectable prescription medicine for adults with type 2 diabetes used to improve blood sugar (glucose) and used to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors.

Warnings

Trulicity may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, trouble swallowing, hoarseness, or shortness of breath. If you have a symptom, tell your doctor.

Ask your doctor how to recognize the serious side effects below and what to do if you think you have one:

Inflamed pancreas (pancreatitis). Stop using Trulicity and call your healthcare provider right away if you have severe pain in your stomach area (abdomen), with or without vomiting, that will not go away. You may feel the pain from your abdomen to your back.

Changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Trulicity.

Low blood sugar (hypoglycemia). Signs and symptoms of low blood sugar may include dizziness or light-headedness, confusion or drowsiness, headache, blurred vision, slurred speech, fast heartbeat, sweating, hunger, shakiness, feeling jittery, weakness, anxiety, irritability or mood changes.

Serious allergic reactions. Stop using Trulicity and get medical help right away if you have any symptoms of a serious allergic reaction which may include: swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Acute kidney injury. In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration). This may cause kidney problems to get worse.

Severe stomach problems. Trulicity may cause stomach problems, which could be severe.

Common side effects

The most common side effects of Trulicity include nausea, diarrhea, vomiting, abdominal pain and decreased appetite.

These are not all the possible side effects of Trulicity.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Before using

Review these questions with your doctor:

Review the list below with your doctor. Trulicity may not be right for you if:

How to take

Learn more

For more information, call 1-844-TRU-INFO (1-844-878-4636) or go to http://www.TRULICITY.com.

This summary provides basic information about Trulicity but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Trulicity and how to take it. Your doctor is the best person to help you decide if Trulicity is right for you.

Please see full Prescribing Information, including Boxed Warning about possible thyroid tumors including thyroid cancer, andMedication Guide.

Trulicity is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

DG CON BS FEB2020

About DiabetesApproximately 30 million Americans1 and an estimated 463 million adults worldwide have diabetes.2 Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone.1 Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

About Lilly DiabetesLilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes. We offer a wide range of therapies and a continued determination to provide real solutionsfrom medicines and technologies to support programs and more. For the latest updates, visit http://www.lillydiabetes.com/or follow us on Twitter: @LillyDiabetes and Facebook: LillyDiabetesUS.

AboutEli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY

*Primary prevention: Reducing the risk of atherosclerotic cardiovascular disease by preventing or managing risk factors. Secondary prevention: Reducing the risk of another event in people who have had a serious CV incident or procedure.

**In a study, 94% of people said it was easy to use.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Trulicity (dulaglutide) as a treatment for type 2 diabetes and for the reduction of cardiovascular events and its safety profile and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with study findings to date, that Trulicity will receive additional regulatory approvals or that Trulicity will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

PP-DG-US-2722 02/2020 Lilly USA, LLC 2020. All rights reserved.

SOURCE Eli Lilly and Company

http://www.lilly.com

Read more from the original source:
Trulicity (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established...

Read More...

Type 2 diabetes symptoms: Skin that looks and feels this way could be a warning sign – Express

Monday, February 24th, 2020

When a person has type 2 diabetes, its important for them to be diagnosed as early as possible because untreated symptoms can lead to dangerous and sometimes irreversible consequences. These complications include damage to the eyes, nerves and kidneys. Some common diabetes symptoms are fatigue, lethargy, confusion, nausea and increases urination. There is an unusual symptom of the condition which lies in a persons skin - if your skin feels this way it may mean youre at risk of developing the condition.

American Diabetes Association said: Diabetes can affect every part of the body, including the skin.

In fact, such problems are sometimes the first sight that a person has diabetes. Luckily, most skin conditions can be prevented or easily treated if caught early.

Some of these problems are skin conditions anyone can have, but people with diabetes get more easily.

These include bacterial infections, fungal infections and itching. Other skin problems happen mostly or only to people with diabetes.

These include diabetic dermopathy, necrobiosis lipoidica diabeticorum, diabetic blisters and eruptive xanthomatosis.

DONT MISS

Dr David Bradley, assistant professor of endocrinology, diabetes and metabolism at The Ohio State University Wexner Medical Centre in Columbus said: High blood sugar increases the risk of skin infections caused by bacteria and yeast.

"Also, poor circulation and nerve damage caused by diabetes can cause itching, too.

"When blood sugar levels are too high for too long, several changes take place in the body that affect skin health.

"Blood sugar leaves the body through the urine and so when there is too much blood sugar, a person will urinate more and this can result in dehydration and skin.

High blood sugar levels can also lead to inflammation.

Over time, this can dull or over stimulate the immune response.

Nerve and blood vessel damage can also reduce circulation. Poor blood flow can alter the skins structure, especially its collagen.

Without healthy collagen networks, the skin can become stiff and in some cases, brittle as collagen is necessary for proper wound healing.

Read this article:
Type 2 diabetes symptoms: Skin that looks and feels this way could be a warning sign - Express

Read More...

Diabetes and ED: Symptoms, Treatment – University of Utah Health Care

Tuesday, February 18th, 2020

Feb 18, 2020 7:00 AM

More than 30 million people in the United States have diabetes. About seven million of those people dont know they have it. Symptoms of untreated diabetes include:

Believe it or not, erectile dysfunction (ED) can also be a symptom of diabetes. In fact, half of men diagnosed with diabetes experience ED within ten years of their diagnosis.

We see quite a few men for erectile dysfunction that end up being diagnosed with diabetes after their visit with us. Most people dont think about the penis being an indicator of other, underlying health issues, but it really is a good barometer.

In order to get an erection, men need healthy blood vessels and nerves. High blood sugar levels, a symptom of diabetes, can damage blood vessels as well as the nerves that control sexual stimulation. Because diabetes can cause the inner lining of blood vessels to function abnormally, it can affect blood flow to the penis, which is how you get and maintain an erection.

Managing your diabetes can stop the progression of ED, but sometimes symptoms dont improve because of nerve damage. There are many treatment options for ED if you dont see an improvement after getting your diabetes under control.

Oral medications typically work about 50 percent of the time for men with diabetes. Penile pumps are also good options, if medications dont work. Other men may choose injection therapy, which is a treatment where you inject the penis with a small needle when you want an erection.

Penile implants are another ED treatment. Implants last 1215 years on average.

All of these treatment options have pros and cons. Men should consider what works best for their lifestyles when chatting with their provider about the best choice for them.

Erectile dysfunction is frustrating and stressful for men and their partners. Its not something people should just live with, Dr. Hotaling said. If youre struggling with ED, talk to your health care provider. Sometimes its an unrelated problem. Other times, its linked to something more serious, like diabetes or heart disease. Regardless, its worth getting treated.

Read the original here:
Diabetes and ED: Symptoms, Treatment - University of Utah Health Care

Read More...

Oral Adjunctive Therapy Yields Positive Results for Adults with Type 1 Diabetes – Pharmacy Times

Tuesday, February 18th, 2020

Positive results have been announced from part 2 of the phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D).

TTP399 is a novel, once-daily, liver-selective glucokinase activator. Simplici-T1, a multi-center, randomized, 12-week trial, investigated the efficacy and safety of 800 mg of TTP399 compared with placebo in 85 patients with T1D on optimized insulin therapy.

The trial successfully achieved its primary objective, which was analyzed using 2 statistical approaches to evaluating the effect of TTP399. The primary statistical analysis evaluated the effect on long-term blood sugar (HbA1c) regardless of treatment adherence or notable change in insulin administration.

Under the primary statistical analysis, the trial achieved its primary objective by demonstrating statistically significant improvements in HbA1c for TTP399 compared with placebo at week 12.

TTP399 was well tolerated with similar incidences of treatment-emergent adverse events (AEs) overall and by system organ class in both treatment groups. The study had no report of diabetic ketoacidosis in either treatment group. There was no incidence of severe hypoglycemia in the treated group and 1 incident in the placebo group.

Patients taking TTP399 experienced fewer symptomatic hypoglycemic episodes: 2 subjects taking TTP399 reported at least 1 AE compared with 8 subjects taking placebo.

In order to rule out that the reduction of HbA1c was driven by the administration of excess insulin (3 or more units per day), a second statistical analysis was performed. Based on this analysis, patients treated with TTP399 achieved a statistically-significant, placebo-subtracted reduction in HbA1c. Patients taking placebo experienced a 0.11% increase in HbA1c from a mean study baseline HbA1c of 7.6% following a multi-week insulin optimization period prior to the administration of study treatment.

Daily time in range was improved by approximately 2 hours in patients treated with TTP399 relative to placebo (p=0.03). TTP399 treatment reduced the total daily meantime bolus insulin dose by 11% relative to baseline (p=0.02), whereas the placebo-treated group experienced a 3% decrease relative to baseline.

TTP399 selectively activates glucokinase (GK), a key regulator of glucose metabolism in the liver. This activation has been shown to increase glucose utilization, which in turn lowers blood glucose. Simplici-T1 is the first study to test activation of GK in patients with T1D, evaluating daily oral TTP399 as an adjunct to insulin therapy.

Reference

See original here:
Oral Adjunctive Therapy Yields Positive Results for Adults with Type 1 Diabetes - Pharmacy Times

Read More...

Keto diet is being used by government to treat veterans’ diabetes – Insider – INSIDER

Tuesday, February 18th, 2020

Diabetes is one of the largest, most expensive problems facing America's veterans, and the US government is staking its hopes for a solution on an unconventional treatment: the popular keto diet.

The Department of Veterans' Affairs (VA) has launched a partnership with a digital therapeutics startup Virta Health to treat diabetic veterans using the low-carb, high-fat keto diet, at no cost to the vets or the VA.

The partnership, first announced in May 2019, has enrolled 400 veterans into Virta's program, which includes personalized nutrition plans and online access to health coaches and physicians.

So far, the results have been promising, according to the company's data. A pilot program with the VA found that half of the participating veterans achieved blood sugar levels below the threshold for diabetes after three months on Virta's program. And the treatment successfully reduced medications, including insulin, by 53% across the entire group.

But some experts have raised concerns that there may be unforeseen health consequences following this kind of treatment, and that the VA's buy-in will lend legitimacy to what is still an experimental treatment.

Prior to working with the VA, Virta had been studying keto as a treatment for diabetes for over two years.

Diabetes is an inability to balance blood sugar.Reducing carbs manages the problem at the source by preventing blood sugar from rising in the first place, according to Dr. Mark Cucuzzella, a professor at West Virginia University School of Medicine, a US Air Force Reservist, and a marathon runner who has published several studies on keto and diabetes.

Hollis Johnson/INSIDER "The most impactful thing on your blood glucose is the amount of carbs in your diet. The low-carb diet is effective because it lowers the insulin load," Cucuzzella, whois not affiliated with Virta, told Insider in an interview. "Insulin is the master switch."

Medications like insulin can mitigate diabetes symptoms by managing blood sugar levels. But keto can help patients reduce medications, said Dr. Sarah Hallberg, medical director for Virta.

Eating carbohydrates causes blood sugar to rise, but eating fats does not. It means diabetic patients can get their daily calories without needing to use insulin to balance out spiking blood sugar levels.

"Standard treatment puts people on a one-way street of progression for diabetes, with temporary pharmaceutical treatment that will have to be added on to," Hallberg told Insider. "We're able to give people another lane going the other way by bringing blood sugar into non-diabetic range while reducing and eliminating medication."

That doesn't mean keto can cure diabetes.

Virta refers to its treatment as a "reversal" of diabetes. In layman's terms, this means the disease is in remission. The treatment only works as long as the low-carb diet is maintained. As soon as carbs are re-introduced, the same problems with blood sugar and insulin emerge.

A keto diet is any eating plan that pushes the body into a state of ketosis when it begins producing substances called ketones, explained Dr. Ethan Weiss, a cardiologist and founder of a ketone-detecting device. (Weiss previously served as a medical advisor for Virta.)

"Keto" typically refers to eating plans in which a majority of daily calories come from fat, along with some protein and minimal carbs.People with diabetes could cut their carb intake to as low as 30 grams a day and still be healthy.

But the key to medical keto is going beyond counting macronutrients. Instead, it's important to focus onwhole-food sources of fats, cutting carbs without completely eliminating nutrient-rich foods like veggies.

Vietnam war veterans among other guests listen to U.S. President Barack Obama at the Memorial Day observance at Arlington National Cemetery in Washington, U.S., May 30, 2016. REUTERS/Yuri Gripas

It's not clear what long-term health effects the keto diet might have.

The Physicians Committee for Responsible Medicine, a group of medical experts who advocate a plant-based diet, sent a letter to VA officials asking them to reconsider the partnership, and keto treatment, based on evidence that a high-fat, low-carb diet could potentially increase risks of diabetes, particularly diets high in saturated fat.

Skeptics have also noted that most of the data showing keto can treat diabetes is based on studies led and funded by Virta itself. There is barely any hard data on keto's health effects beyond two years on the diet.

Hallberg acknowledged the lack of long-term evidence, but said the same problem has plagued nearly every other type of therapeutic diet (with the exception of the Mediterranean diet).

"There's needs to be a hard outcome, long-term trial looking at a variety of eating patterns, no question," she said.

But in the meantime, diabetes continues to be diagnosed in record numbers, particularly among military veterans.

"Do we have 10-20 years to wait for that?We're in the midst of an unprecedented diabetes and obesity epidemic," she said. "We have to do something now."

Read more:

Nutrition experts react to the keto diet's new ranking as one of the worst diets of 2020

There's a Mediterranean version of the keto diet that restricts red meat and trades butter for olive oil

The keto diet makes mice better at fighting the flu another clue about how the high-fat, low-carb plan changes the body

View original post here:
Keto diet is being used by government to treat veterans' diabetes - Insider - INSIDER

Read More...

Funds will help Y to focus on diabetes – Marco News

Tuesday, February 18th, 2020

Submitted Published 5:02 a.m. ET Feb. 17, 2020

Afterschool children promote the Y's upcoming participation in the major countywide fundraiser, Give Where You Live Collier.(Photo: Photo provided)

As fundraisers go, this one is a biggie for the YMCA of South Collier (Marco Y).

In a nutshell, the Y collects money for a Countywide drive called Give Where You Live Collier, and then gets it back (and then some) by way of matching funds.

The major fundraiser serves 40 pre-selected non-profits (of which the Marco Y is one) that will benefit from the 24-hour fundraiser taking place noon Feb. 19 to 11:59 a.m. Feb. 20.

Aquatics, sports and specialty camps director Morgan Joseph instills the importance of physical activities to some of the Y's early learners (pre-school).(Photo: Photo provided)

The participating organizations do their own fundraising, and money raised is swelled with matching funds from the Community Foundation of Collier County and Richard M. Schultze Family Foundation.

This year, Marco's Y is focusing its campaign on diabetes prevention and supporting its specialty summer camps for diabetic children.

On-site nurse Monica Ramos delights an early learning (pre-school) student by letting her hear heartbeats.(Photo: Photo provided)

Described as a "growing epidemic," diabetes cases (including types 1 and 11) have risen more than 30 percent since 2000, with many more going undiagnosed until a medical crisis occurs.

The Y's development director, Charlie Vickaryous, notes that 2020 will mark the third year that the organization has partnered with Help a Diabetic Child and Core Health Partners to provide the camp.

Depending on money raised, a second camp is envisaged. In addition, the Y will incorporate an extensive diabetes prevention and intervention program into all summer camp sessions, which serve more than 600 children throughout southern Collier County.

The YMCA of South Collier is a major human service organization providing support for all ages and all income levels throughout Southern Collier County, including Marco, Goodland, East Naples, Everglades City and surrounding areas. More than 10,000 people 2,000 of whom are children benefit each year.

For more information, contact Vickaryous at commdev@marcoy.org - or call 394-9622.

Read or Share this story: https://www.marconews.com/story/news/2020/02/17/funds-help-y-focus-diabetes/4771791002/

Original post:
Funds will help Y to focus on diabetes - Marco News

Read More...

Page 32«..1020..31323334..4050..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick